


Quality Performance



Detailed Quality Reference Guide



Includes a description & best practices for all quality measures



Catalyst
HEALTH NETWORK

Quality Detail Rev. 04/18/2023 | [Contents](#)

Breast cancer screening

The percentage of women ages 50 to 74 who had a mammogram to screen for breast cancer

Eligible Population	
Ages	Women 50-74 years
Measurement	27 months to identify the numerator

Administrative Specification	
Denominator	Female patient(s) 52-74 years of age
Numerator	A screening mammogram is recommended for women 50-74 years of age Patient(s) 52-74 years of age who had a screening mammogram in last 27 reported months

Codes to identify breast cancer screening:

CPT	HCPCS	ICD-CM Procedure	Revenue	LOINC
77055-57, 77061-63, 77065-67	G0202, G0204, G0206	87.36, 87.37	0401, 0403	24604-1, 24605-8, 24606-6, 24610-8, 26175-0, 26176-8, 26177-6, 26287-3, 26289-9, 26291-5, 26346-7, 26347-5, 26348-3, 26349-1, 26350-9, 26351-7, 36319-2, 36625-2, 36626-0, 36627-8, 36642-7, 36962-9, 37005-6, 37006-4, 37016-3, 37017-1, 37028-8, 37029-6, 37030-4, 37037-9, 37038-7, 37052-8,

Quality Measures

The specific measures Catalyst practices a

Comprehensive list of all quality measures included in Catalyst payer contracts.

Measures vary by payer contract.

Quality Measures included in **most** contracts:

- Breast Cancer Screening
- Colorectal Cancer Screening
- Diabetes: Retinal Eye Exam
- Diabetes: HbA1c control (less than 8%)
- Child & Adolescent Well-Care Visits 3-21 years
- Childhood immunization status

- 3 Breast cancer screening
- 5 Cervical cancer screening
- 7 Colorectal cancer screening
- 9 Chlamydia screening in women
- 11 Diabetes: Retinal eye exam
- 13 Diabetes: Hemoglobin A1c testing
- 15 Diabetes: Hemoglobin A1c control (<8.0%)
- 17 Diabetes: Kidney Health Evaluation (KED)
- 19 Controlling high blood pressure
- 20 Childhood immunization status (Combination 3)
- 23 Depression screening
- 24 Well child visits in the first 30 months of life
- 26 Child and Adolescent Well-Care Visits 3-21 years
- 28 Coronary Artery Disease (CAD): Patients currently taking a statin
- 29 Statin therapy for patients with cardiovascular disease
- 31 Diabetes: Patients compliant with prescribed statin-containing medication
- 33 Asthma medication ratio
- 35 Persistence of beta-blocker treatment after heart attack
- 37 Use of opioids at high dosage
- 39 Appropriate testing for pharyngitis
- 41 Appropriate treatment for upper respiratory infection (URI)
- 43 Avoid antibiotics for acute bronchitis/bronchiolitis
- 45 Imaging in uncomplicated low back pain
- 47 Plan all-cause readmissions (actual to expected)

KED Quality Measure Opportunity



How to perform in this measure

- The most efficient lab for addressing this measure is the **ACR (albumin to creatinine ratio test) + eGFR (estimated Glomerular filtration rate)**
- **For all diabetic patients**, order and complete labs routinely during their 6 month follow up or Annual Wellness visit
- Discuss the importance of kidney screening with diabetic patients

Diabetes: Kidney Health Evaluation (KED)

Percentage of members age 18 to 85 with diabetes (Type 1 and Type 2) who had a kidney health evaluation during the measurement year

Eligible Population	
Ages	Members age 18 through 85 years old
Measurement	12 Months
Administrative Specification	
Denominator	Members 18-85 years of age having diabetes Diagnosis codes to identify diabetes:
	ICD-CM Diagnosis 250 - 250.93, 357.2, 362.0 - 362.07, 366.41, E10*, E11*, E13*, O24.011-O24.83
Numerator	Documentation within the medical record of any of the following meet criteria for a kidney health evaluation: <ul style="list-style-type: none">• At least 1 estimated glomerular filtration rate (eGFR); AND• At least 1 urine albumin-creatinine ratio (uACR) test identified by one of the following:<ul style="list-style-type: none">- A quantitative urine albumin test AND a urine creatinine test 4 or less days apart; OR- A uACR

Exclusions:

Members who meet any of the following criteria are excluded:

- Received hospice and/or palliative care during the measurement year
- Medicare members ages 66 and older who were enrolled in an Institutional Special Needs Plan (I-SNP) or were living long-term in an institution during the measurement year
- Members who have no diagnosis of diabetes in any setting and a diagnosis of polycystic ovarian syndrome, gestational or steroid-induced diabetes during measurement year or year prior
- Age 66 or older with both frailty and advanced illness, or members ages 81 and older with frailty
- Members with End-Stage Renal Disease (ESRD), or who were on dialysis during the measurement year

KED Quality Measure Opportunity



CPT II codes and exclusions to consider

- Are **exclusion codes being utilized** for patients that don't have a clinical reason for this test?
- Is the patient already established with an **endocrinologist** or **nephrologist** that may have already performed this lab?
- **CPTII Coding Tip:** Adding a CPT II Code ensures the lab is measured. If the patient has labs from another facility don't forget to add the CPT II codes to capture the value.
 - **3060F** Positive Microalbuminuria test result documented and reviewed
 - **3061F** Negative microalbuminuria test result documented and reviewed
 - **82043** Urine microalbumin semi quantitative
 - **82570** Creatinine; other source

Codes to identify exclusions:

Description	CPT	ICD-CM Diagnosis
Dialysis Procedure	90935, 90937, 90945, 90945, 90947, 90997, 90999, 99512	-
ESRD Diagnosis	-	N18.5-6, Z99.2
Steroid-induced Diabetes	-	E09.9
Gestational Diabetes	-	O24.4
Polycystic Ovarian Syndrome Diagnosis	-	E28.2

Administrative Specification (Continued)

Numerator (Continued)

Estimated Glomerular Filtration Rate (eGFR) Lab Test:

CPT	LOINC
80047, 80048, 80050, 80053, 80069, 82565	48642-3, 48643-1, 50044-7, 50210-4, 50384-7, 62238-1, 69405-9, 70969-1, 77147-7, 88293-6, 88294-4, 94677-2, 96591-3, 96592-1,

Quantitative Urine Albumin Lab Test:

CPT	LOINC
82043	14957-5, 1754-1, 21059-1, 30003-8, 43605-5, 53530-2, 53531-0, 57369-1, 89999-7

Urine Creatinine Lab Test

CPT	LOINC
82570	20624-3, 2161-8, 35674-1, 39982-4, 57344-4, 57346-9, 58951-5

Urine Albumin Creatinine Ratio Test

LOINC
13705-9, 14958-3, 14959-1, 30000-4, 32294-1, 44292-1, 59159-4, 76401-9, 77253-3, 77254-1, 89998-9, 9318-7

Cervical Cancer Screening Quality Measure Opportunity

How to perform in this measure

- Identify if the patient currently has a **gynecologist or OBGYN**. If so, verify & record the date of their last visit or encourage follow up
- Establish completing **routine PAP** during annual wellness visit.

Cervical cancer screening

The percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:

- Women 21-64 years of age** who had cervical cytology performed within the last 3 years.
- Women 30-64 years of age** who had cervical high-risk human papillomavirus (hrHPV) co-testing performed within the last 5 years.
- Women 30-64 years of age** who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.

Eligible Population		
Ages	Women 21-64 years old.	
Measurement	36-months to identify the numerator age 21-29, 60 month for age 30-64.	
Administrative Specification		
Denominator	Women 21 to 64 years old at the end of the measurement year.	
Numerator	<p>The number of women who were screened for cervical cancer. Either of the following meets criteria:</p> <p>Women 21-64 years of age who had cervical cytology during the measurement year or the three years prior to the measurement year.</p> <p>Women 30-64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing during the measurement year or the five years prior to the measurement year and who were 30 years or older on the date of the test.</p>	
Codes to identify cervical cytology:		
CPT	HCPCS	LOINC
88141-43, 88147-48, 88150, 88152-54, 88164-67, 88174-75	G0123-24, G0141, G0143-45, G0147-48, P3000, P3001, Q0091	10524-7, 18500-9, 19762-4, 19764-0, 19765-7, 19766-5, 19774-9, 33717-0, 47527-7, 47528-5
Codes to identify High Risk HPV Test:		
CPT	HCPCS	LOINC
87620 -22, 87624-25	G0476	21440-3, 30167-1, 38372-9, 59263-4, 59264-2, 59420-0, 69002-4, 71431-1, 75694-0, 77379-6, 77399-4, 77400-0, 82354-2, 82456-5, 82675-0

Appropriate Testing for Children with Pharyngitis Quality Measure Opportunity

How to perform in this measure

- Patient presents with correct symptoms complete a **rapid Group A strep test** OR **throat culture** if the patient is 3 months or older
- If an **antibiotic is dispensed** patient enters denominator this requires a follow up test to determine follow up care

Appropriate testing for pharyngitis

Percentage of episodes for members ages 3 years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.

A higher rate indicates appropriate testing and treatment.

Eligible Population	
Ages	3 years of age and older.
Measurement	12 Months. The intake period is from six months prior to the beginning of the measurement year to six months prior to the end of the measurement year. The earliest episode during the intake period is the index episode start date.
Administrative Specification	
Denominator	<p>All members, 3 years of age or older who had an outpatient, telephone, online assessment, observation, or emergency department encounter with a diagnosis of pharyngitis and were dispensed an antibiotic</p> <p>All members 3 years of age and older during the intake period, who had a pharyngitis encounter with:</p> <ul style="list-style-type: none"> • An antibiotic prescribed within three days of the encounter • No antibiotic medication prescribed or refilled within 30 days prior to the encounter or still active on the date of the encounter
Pharyngitis	
ICD-10 Diagnosis	
J02.0, J02.8, J02.9, J03.00, J03.01, J03.80, J03.81, J03.90, J03.91	
Antibiotic medications:	
Descriptor	Prescription
Aminopenicillins	<ul style="list-style-type: none"> • Amoxicillin • Ampicillin
Beta-lactamase inhibitors	<ul style="list-style-type: none"> • Amoxicillin-clavulanate
First generation cephalosporins	<ul style="list-style-type: none"> • Cefadroxil • Cefazolin • Cephalexin
Folate antagonist	<ul style="list-style-type: none"> • Trimethoprim
Lincosylin derivatives	<ul style="list-style-type: none"> • Clindamycin
Macrolides	<ul style="list-style-type: none"> • Azithromycin • Clarithromycin • Erythromycin • Erythromycin ethylsuccinate • Erythromycin lactobionate • Erythromycin stearate
Natural penicillins	<ul style="list-style-type: none"> • Penicillin G potassium • Penicillin G sodium • Penicillin V potassium • Penicillin G benzathine
Penicillinase-resistant penicillins	<ul style="list-style-type: none"> • Dicloxacillin
Quinolones	<ul style="list-style-type: none"> • Ciprofloxacin • Levofloxacin • Moxifloxacin • Ofloxacin

Uncontrolled A1c

A1c > 8%

Strategies

- Routine 3 month follow up visits
- Refer to Care Manager
- New to Diabetes? = Care Team referral for Diabetic education
- Problem with access to Medication = Pharmacy Referral
- Supplemental Data Submission
- CPT II codes to capture value

Diabetes: Hemoglobin A1c control (<8.0%)

The percentage of members age 18 to 75 with diabetes that demonstrate glycemic control, based on a HbA1c level less than 8%.

NEW HEDIS REQUIREMENT FOR THIS MEASURE Document patients race and ethnicity within medical record.

Eligible Population					
Ages	Member age 18 through 75 years old.				
Measurement	12 Months.				
Administrative Specification					
Denominator	Members 18 to 75 years old with diagnosis of type 1 or type 2 diabetes. Diagnosis codes to identify diabetes: ICD-CM Diagnosis 250 – 250.93, 357.2, 362.0 – 362.07, 366.41, E10*, E11*, E13*, O24.011-O24.83				
Numerator	Lab results with most recent HbA1c result value less than 8.0%. Codes to identify HbA1c levels <8.0%: <table border="1"><thead><tr><th>CPT II</th><th>LOINC</th></tr></thead><tbody><tr><td>3044F, 3051F</td><td>4548-4, 4549-2, 17856-6</td></tr></tbody></table>	CPT II	LOINC	3044F, 3051F	4548-4, 4549-2, 17856-6
CPT II	LOINC				
3044F, 3051F	4548-4, 4549-2, 17856-6				
Exclusions: Members who meet any of the following criteria are excluded: <ul style="list-style-type: none">• Received hospice and/or palliative care during the measurement year• Age 66 or older with both frailty and advanced illness• Dispensed dementia medication (Donepezil, Galantamine, Rivastigmine, Memantine)• Members who have no diagnosis of diabetes in any setting and a diagnosis of polycystic ovarian syndrome, gestational or steroid-induced diabetes during measurement year or year prior					

Appropriate Treatment of Children with a URI Quality Measure Opportunity



How to perform in this measure

- Patient enters denominator **after** an URI episode
- Encourage a **follow up** assessment of the patient to determine if more intervention is needed
- Include date for first encounter or ED visit and URI diagnosis plus **no new or refill of antibiotics**

Appropriate treatment for upper respiratory infection (URI)

Percentage of episodes for members 3 months and older who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or 3 days after the diagnosis day (4 days total).

A higher rate indicates appropriate testing and treatment (Update)

Eligible Population																							
Ages	3 months of age and older.																						
Measurement	12 Months.																						
Administrative Specification																							
Denominator	Episodes where the member had an outpatient, observation, telephone, online assessment, or ED visit with a diagnosis of URI. Upper Respiratory Infection Codes That Do Not Need Antibiotics: ICD-10 Diagnosis J00, J06.0, J06.9																						
Numerator	Episodes with no antibiotic prescription on or in the three days following the episode date. The following antibiotic medications should not be prescribed for an upper respiratory infection: Antibiotic Medications																						
	<table border="1"> <thead> <tr> <th>Description</th> <th>Prescription</th> </tr> </thead> <tbody> <tr> <td>Aminoglycosides</td> <td> <ul style="list-style-type: none"> Amikacin Gentamicin Streptomycin Tobramycin </td> </tr> <tr> <td>Aminopenicillins</td> <td> <ul style="list-style-type: none"> Amoxicillin Ampicillin </td> </tr> <tr> <td>Beta-lactamase Inhibitors</td> <td> <ul style="list-style-type: none"> Amoxicillin-clavulanate Ampicillin-sulbactam Piperacillin-tazobactam </td> </tr> <tr> <td>First generation cephalosporins</td> <td> <ul style="list-style-type: none"> Cefadroxil Cefazolin Cephalexin </td> </tr> <tr> <td>Fourth generation cephalosporins</td> <td> <ul style="list-style-type: none"> Cefepime </td> </tr> <tr> <td>Ketolides</td> <td> <ul style="list-style-type: none"> Telithromycin </td> </tr> <tr> <td>Lincomycin derivatives</td> <td> <ul style="list-style-type: none"> Clindamycin Lincomycin </td> </tr> <tr> <td>Macrolides</td> <td> <ul style="list-style-type: none"> Azithromycin Clarithromycin Erythromycin </td> </tr> <tr> <td>Miscellaneous antibiotics</td> <td> <ul style="list-style-type: none"> Aztreonam Chloramphenicol Dalfoipristin-quinupristin Daptomycin Linezolid Metronidazole Vancomycin </td> </tr> <tr> <td>Natural penicillins</td> <td> <ul style="list-style-type: none"> Penicillin G benzathine- procaine Penicillin G potassium Penicillin G procaine Penicillin G Sodium Penicillin V potassium Penicillin G benzathine </td> </tr> </tbody> </table>	Description	Prescription	Aminoglycosides	<ul style="list-style-type: none"> Amikacin Gentamicin Streptomycin Tobramycin 	Aminopenicillins	<ul style="list-style-type: none"> Amoxicillin Ampicillin 	Beta-lactamase Inhibitors	<ul style="list-style-type: none"> Amoxicillin-clavulanate Ampicillin-sulbactam Piperacillin-tazobactam 	First generation cephalosporins	<ul style="list-style-type: none"> Cefadroxil Cefazolin Cephalexin 	Fourth generation cephalosporins	<ul style="list-style-type: none"> Cefepime 	Ketolides	<ul style="list-style-type: none"> Telithromycin 	Lincomycin derivatives	<ul style="list-style-type: none"> Clindamycin Lincomycin 	Macrolides	<ul style="list-style-type: none"> Azithromycin Clarithromycin Erythromycin 	Miscellaneous antibiotics	<ul style="list-style-type: none"> Aztreonam Chloramphenicol Dalfoipristin-quinupristin Daptomycin Linezolid Metronidazole Vancomycin 	Natural penicillins	<ul style="list-style-type: none"> Penicillin G benzathine- procaine Penicillin G potassium Penicillin G procaine Penicillin G Sodium Penicillin V potassium Penicillin G benzathine
Description	Prescription																						
Aminoglycosides	<ul style="list-style-type: none"> Amikacin Gentamicin Streptomycin Tobramycin 																						
Aminopenicillins	<ul style="list-style-type: none"> Amoxicillin Ampicillin 																						
Beta-lactamase Inhibitors	<ul style="list-style-type: none"> Amoxicillin-clavulanate Ampicillin-sulbactam Piperacillin-tazobactam 																						
First generation cephalosporins	<ul style="list-style-type: none"> Cefadroxil Cefazolin Cephalexin 																						
Fourth generation cephalosporins	<ul style="list-style-type: none"> Cefepime 																						
Ketolides	<ul style="list-style-type: none"> Telithromycin 																						
Lincomycin derivatives	<ul style="list-style-type: none"> Clindamycin Lincomycin 																						
Macrolides	<ul style="list-style-type: none"> Azithromycin Clarithromycin Erythromycin 																						
Miscellaneous antibiotics	<ul style="list-style-type: none"> Aztreonam Chloramphenicol Dalfoipristin-quinupristin Daptomycin Linezolid Metronidazole Vancomycin 																						
Natural penicillins	<ul style="list-style-type: none"> Penicillin G benzathine- procaine Penicillin G potassium Penicillin G procaine Penicillin G Sodium Penicillin V potassium Penicillin G benzathine 																						

Chlamydia Screening Quality Measure Opportunity

How to perform in this measure

- Perform routine urine screenings during an annual wellness for **16 – 24 sexually active or pregnant females**
- Identify if the patient has a **gynecologist or OBGYN**
- Discuss **importance** of screening



Chlamydia screening in women

Percentage of female members ages 16–24 who were identified as sexually active and had at least one test to screen for chlamydia during the measurement year.

UHC & CIGNA MEASURE ONLY

Eligible Population							
Ages	Women 16–24 years old.						
Measurement	12 Months.						
Administrative Specification							
Denominator	Patient(s) 16–24 years of age with a diagnosis of sexual activity or claim for birth control.						
Numerator	<p>Patient(s) 16–24 years of age that had a chlamydia screening test in last 12 reported months.</p> <p>During the 12-month report period did the patient have one or more claims with one of the following:</p> <p>Diagnosis: 1) Sexual activity, 2) pregnancy</p> <p>AND the service is NOT laboratory.</p> <p>Chlamydia Screening Test:</p> <table border="1"> <thead> <tr> <th>CPT</th> <th>LOINC</th> </tr> </thead> <tbody> <tr> <td>UHC: 87110, 87270, 87320, 87490 -92, 87810</td> <td>14463-4, 14464-2, 14467-5, 14474-1, 14513-6, 16600-9, 21190-4, 21191-2, 21613-5, 23838-6, 31775-0, 31777-6, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45068-4, 45069-2, 45075-9, 45076-7, 45084-1, 45091-6, 45095-7, 45098-1, 45100-5, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 560-3, 6349-5, 6354-5, 6355-2, 6356-0, 6357-8, 80360-1, 80361-9, 80362-7, 91860-7</td> </tr> <tr> <td>Cigna: 87110</td> <td></td> </tr> </tbody> </table>	CPT	LOINC	UHC: 87110, 87270, 87320, 87490 -92, 87810	14463-4, 14464-2, 14467-5, 14474-1, 14513-6, 16600-9, 21190-4, 21191-2, 21613-5, 23838-6, 31775-0, 31777-6, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45068-4, 45069-2, 45075-9, 45076-7, 45084-1, 45091-6, 45095-7, 45098-1, 45100-5, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 560-3, 6349-5, 6354-5, 6355-2, 6356-0, 6357-8, 80360-1, 80361-9, 80362-7, 91860-7	Cigna: 87110	
CPT	LOINC						
UHC: 87110, 87270, 87320, 87490 -92, 87810	14463-4, 14464-2, 14467-5, 14474-1, 14513-6, 16600-9, 21190-4, 21191-2, 21613-5, 23838-6, 31775-0, 31777-6, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45068-4, 45069-2, 45075-9, 45076-7, 45084-1, 45091-6, 45095-7, 45098-1, 45100-5, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 560-3, 6349-5, 6354-5, 6355-2, 6356-0, 6357-8, 80360-1, 80361-9, 80362-7, 91860-7						
Cigna: 87110							

Annual Visit Checklist

Practice tool / resource to consider using to improve overall quality performance

- Utilize during pre-charting for patients completing an annual wellness visit
- Have patient complete during check in or add to pre wellness questionnaire
- MA/RN review with patient during the rooming process

[AWV Gap Checklist v5 .pdf](#)

AWV Gap Checklist

Patient Name _____ Patient DOB _____ Patient Age _____
 PCP Name _____ DOS _____

Depression Screening *Cigna*
 Members 12 years of age and older (Every 12 months)

PHQ9
 Date _____ Result _____

PHQ2
 Date _____ Result _____

HCPC: G0444

Colorectal Cancer Screening
 Members 45 to 75 of age

Exclusion
 Colorectal cancer HCPC: G0213-00215, G0231
 Total colectomy CPT: 44150-44153, 44155-44158, 44210-44212
 History of Total Colectomy, History of Colon Cancer, Personal History of other malignant neoplasm of rectum, rectosigmoid junction, anus, or large intestine, hospice, palliative care, 66 or older with both frailty and advanced illness.

Fecal Occult Blood Test (FOBT) Needed Annually
 Date _____ Result _____

CPT: 82270, 82274
 HCPC: G0128

Cologuard/FIT DNA (Needed every 3 years)
 Date _____ Result _____

CPT: 81528
 HCPC: G0464

Sigmoidoscopy (Needed every 5 years)
 Date _____ Result _____

CPT: 45330-45335, 45307, 45338, 45340-45342, 45346, 45347, 45349-45350, 74261-74263 HCPC: G0904

Colonoscopy (Needed every 10 years)
 Date _____ Result _____

CPT: 44388-44394, 44397, 45355, 45378-45393, 44401-44408, 45398
 HCPC: G0108, G0121

Cervical Cancer Screening
 Female Members 21 to 64 years of age who have had a PAP smear performed in the last 3 years, 30 to 64 years of age who had hrHPV testing or cervical cytology/hrHPV co-testing within the last 5 years

Exclusion
 Agenesis & aplasia of cervix, prolapse of vaginal vault after hysterectomy, absence of cervix and/or uterus, hospice, palliative care

Last PAP smear completed
 Date _____ Result _____

CPT: 80141-80143, 8847-88148, 88150, 88151-88154, 88164-88167, 88174-88175
 High Risk HPV Test: 87620-87622, 87624-87625 HCPC: G0476
 Hysterectomy CPT: 59215, 58908, 57540, 57545, 57560, 57565, 57556, 58150, 58152, 58300, 58310, 58340, 58340, 58362, 58363, 58267, 58370, 58275, 58280, 58285, 58290-58296, 58348, 58350-58354, 58370-58373, 58951, 58953, 58954, 58956, 58955

Controlling Blood Pressure
 Members 18 to 85 years of age

Date _____ Result _____

CPT II: 3074F, 3075F, 3076F, 3077F, 3078F, 3079F, 3080F

Breast Cancer Screening
 Female Members 50-74 of age (Every 27 months)

Exclusion
 History of Bilateral Mastectomy, Absence of L or R Breast/
 Bilateral CPT: 19180, 19200, 19220, 19240, 19303-19307 With Modifier 50 or modifier code 09950*ICD-CM: 85.42, 85.44, 85.46, 85.48, 0HTV02Z
 Unilateral CPT: 19180, 19200, 19220, 19240, 19303-19307 ICD-CM: 85.41, 85.43, 85.45, 85.47, 0HTV02Z, 0HTV02Z Absence of Left Breast ICD-CM: 206.12, Absence of Right Breast 206.11, History of Bilateral Mastectomy 200.13

Last Mammogram completed
 Date _____ Result _____

Mammogram Ordered
 Date _____ Result _____

Screening
 CPT: 77055-77057, 77068-77063, ICD-CM: 87.36, 87.37
 77065-77067 HCPC: G0202, G0204, G0208

Chlamydia Screening *UHC & Cigna*
 Female Members 16 to 24 years of age (Every 12 months)

Last STD screening completed
 Date _____ Result _____

Screening
 UHC CPT: 87110, 87270, 87320, 87490-87492, 87810 Cigna: 87110

Diabetes: Retinal Eye Exam
 Members 18 to 75 of age (Annually)

Exclusion
 Hospice, Palliative Care

Last Retinal Exam completed
 Date _____ Result _____

CPT II: 2022F, 2023F, 2024F, 2025F, 2026F, 2033F, 3072F

Diabetes: Hemoglobin A1c Testing
 Members 18 to 75 of age (Annually)

Exclusion
 Hospice, Palliative Care, No diagnosis of Diabetes

Last HBA1c completed
 Date _____ Result _____


CPT II: 3044F, 3046F, 3051F, 3052F

Diabetes: Compliance With Prescribed Statin-Containing Medication
 Members 40 to 75 of age (minimum of 80% compliance)

Prescribed Statin _____ Dose/ga _____

Gap closed by prescribing statin medication with 80% of patient adherence.

catalysthealthnetwork.net v5 09/16/22



CPT Codes






CPT-II Codes

Condition and/or Metric	CPT II Code(s)
Adult BMI	3008F Body Mass Index (BMI) documented *use ICD 10 codes to indicate specific BMI scores
Diabetes: HbA1c Testing	3044F Most recent A1c level < 7.0% 3051F Most recent A1c level > 7.0 - < 8.0 3052F Most recent A1c level > 8.0 < 9.0 3046F Most recent A1c level >9%
Diabetes: Retinal Eye Exam Performed	2022F Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed 2024F 7 standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist documented and reviewed 2026F Eye imaging validated to match diagnosis from 7 standard field stereoscopic photos results documented and reviewed 3072F Low risk for retinopathy (no evidence of retinopathy in the prior year) 2023 F Dilated retinal eye exam interpreted by eye professional documented/ reviewed without evidence of retinopathy 2025F 7 standard field stereoscopic photos with interpretation by eye professional without retinopathy 2033F Eye imaging validated to match dx from 7 standard stereoscopic photos results without retinopathy
Diabetes: LDL-C Screening Diabetes: LDL-C Control (< 100 mg/dL) Hyperlipidemia	3048F Most recent LDL-C < 100 mg/dl 3049F Most recent LDL-C 100-129 mg/dL 3050F Most recent LDL-C ≥ 130 mg/dL
Diabetes: Medical Attention for Nephropathy	3060F Positive microalbuminuria test result documented and reviewed 3061F Negative microalbuminuria test result documented and reviewed 3062F Positive macroalbuminuria test result documented and reviewed 3066F Documentation of treatment for nephropathy (patient receiving dialysis, patient being treated for ESRD, CKD, ARF, or renal insufficiency, any visit to a nephrologist) 4010F ACE inhibitor or ARB therapy prescribed
Diabetes: Kidney Health Evaluation (KED)	80047 eGFR: Basic metabolic panel (calcium, ionized) 80048 eGFR: Basic metabolic panel (calcium, total) 80050 eGFR: General health panel 80053 eGFR: Comprehensive metabolic panel 80069 eGFR: Renal function panel 82565 eGFR: Creatinine; blood 82043 Urine (e.g., micro albumin) semi quantitative (e.g., reagent strip assay) 82570 Creatinine; other source (e.g., urine)

Condition and/or Metric	CPT II Code(s)
Hypertension: Blood Pressure Controlled	3074F Most recent systolic blood pressure < 130 mm Hg 3075F Most recent systolic blood pressure 130-139 mm Hg 3077F Most recent systolic blood pressure > 140 mm Hg 3078F Most recent diastolic blood pressure < 80 mm Hg 3079F Most recent diastolic blood pressure 80-89 mm Hg 3080F Most recent diastolic blood pressure >90
Rheumatoid Arthritis Management	4187F 1 or more DMARD dispensed, prescribed or administered
Tobacco Use	1034F Current tobacco smoker 1035F Current smokeless tobacco user 1036F Current tobacco non-user 4000F Tobacco use cessation intervention, counseling 4001F Tobacco use cessation intervention, pharmacologic therapy
Prenatal/Post-partum Care	0500F Initial prenatal care visit 0501F Prenatal flow sheet documented in medical record by first prenatal visit 0503F Postpartum care visit
Immunizations	1030F Influenza immunization status assessed 4274F Influenza immunization administered or previously received 4037F Influenza immunization ordered or administered 1022F Pneumococcus immunization status assessed 4040F Pneumococcal vaccine administered or previously received
Diagnosis of COPD	3023F Spirometry results documented and reviewed 3025F Spirometry test results demonstrate FEV/FVC less than 70% with COPD symptoms (dyspnea, cough/sputum, wheezing) 3027F Spirometry test results demonstrate FEV/FVC greater than or equal to 70% or patient does not have COPD symptoms 3023F Spirometry results documented and reviewed 3025F Spirometry test results demonstrate FEV/FVC less than 70% with COPD symptoms (dyspnea, cough/sputum, wheezing) 3027F Spirometry test results demonstrate FEV/FVC greater than or equal to 70% or patient does not have COPD symptoms
Osteoporosis Management for Women with Fracture	4005F Pharmacologic therapy (other than vitamins/minerals) for osteoporosis prescribed 3095F Central Dual-energy X-Ray Absorptiometry (DXA) results documented

Condition and/or Metric	CPT II Code(s)
Care for Older Adults	<p>1157F Advance care plan or similar legal document present in the medical record</p> <p>1158F Advance care planning discussion documented in the medical record</p> <p>1123F Advance Care Planning discussed and documented; advance care plan or surrogate decision maker documented in the medical record</p> <p>1160F Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record</p> <p>1170F Functional status assessed</p> <p>0521F Plan of care to address pain documented</p> <p>1125F Pain severity quantified; pain present</p> <p>1126F Pain severity quantified; no pain present</p>



Annual Wellness Card



Has the patient completed an Annual Wellness appointment?

For Diabetic Patients

- A1c in control: < 8% (annually) + CPTII
- KED: Urine Albumin Creatinine Ratio & eGFR (annually) *same visit
- Retinal Eye Exam (annually)
- Statin Therapy

For Hypertensive Patients

- Complete blood pressure check + use CPTII codes to report values
- In control: < 139/89
- Statin therapy

Review Immunization Status

Colorectal Screening Age 45 - 75

- Colonoscopy every 10 years or
- Flexible sigmoidoscopy every 5 years or
- Cologuard every 3 years or
- FOBT yearly

Female Patient Screenings

- Breast Cancer Screening/Mammogram: Age 50-74 (every 27 months)
- Cervical Cancer Screening: Age 21-64 (every 3 or 5 years)
- Chlamydia Screening: Age 16-24 (annually if sexually active or have a claim for birth control)

Quick Reference CPTII codes

A1c Value Indicators

- 3044F – A1c < 7.0%
- 3051F – A1c > 7.0% - < 8.0%
- 3052F – A1c > 8.0 % <9.0%

Blood Pressure Value Indicators

- 3074 < 130 mm systolic
- 3075 130 -139 mm systolic
- 3077 > 140 mm systolic
- 3078 < 80 mm diastolic
- 3079 80 – 89 mm diastolic